Turn this list into pipeline.
Pharmaceutical Companies in Cardiff: 73 Active Firms (2026)
Pharmaceutical companies in Cardiff develop, manufacture, import or distribute medicines under MHRA oversight across the city region.
Buying centres cluster around regulated supply-chain procurement, pharmacy and wholesaler operations, clinical-research support, and manufacturing-quality functions. Buyers are mainly business and healthcare organisations rather than consumers: hospital pharmacy teams, clinical research operators, wholesalers, regulated healthcare suppliers and service providers that need medicines-linked infrastructure. Engagements tend to be specialist and licence-checked, with due diligence on good manufacturing practice, good distribution practice, traceability, batch control, quality release and pharmacovigilance responsibilities. Cardiff firms in this segment usually look more like lean, revenue-generating specialists than discovery-only ventures, so procurement often sits with operational and quality teams as much as commercial budget holders.
Read more
Cardiff has 73 actively trading pharmaceutical companies, making this a small city-region cohort rather than a broad national cluster. Reported employment totals 104 people, which fits the pattern of lean manufacturers, importers, wholesalers and medicines-service specialists rather than large plant-heavy operations. The commercial base appears narrow at the upper end: only a small minority sits above the £5M turnover threshold, while many remain closer to owner-managed or early-commercial scale. For researchers, that points to a market where individual permissions, supply relationships and customer concentration matter more than headline company volume.
Human medicines activity is licensing-led rather than just sector-label-led. The MHRA sets standards, evaluates new treatments, approves clinical trials, licenses medicines and oversees pharmacovigilance, as described by ABPI. GOV.UK guidance makes the operating split fairly plain: making, assembling or importing human medicines requires a manufacturer’s licence, good manufacturing practice and site inspection; wholesale supply away from the patient route requires a wholesale distribution licence and good distribution practice. Marketing authorisation and cost-effectiveness review also shape market access, so Cardiff firms serving healthcare and pharmacy customers tend to carry regulatory evidence, quality systems and distribution records as part of the commercial proposition.
Cardiff’s cohort appears likely to remain specialist rather than volume-led. Early-commercial entrants can find niches in regulated services, import, distribution and medicine-adjacent infrastructure, but scale-up paths tend to be constrained by licensing burden, inspection readiness, working-capital needs and the cost of proving quality systems to cautious buyers. Consolidation may come through supply-chain partnerships or acquisition of permissions and customer contracts, rather than through a broad wave of new manufacturing capacity. The firms with the clearer prospects are likely to be those that can show repeatable compliance, dependable distribution and a defensible role in healthcare supply chains.
73
Active firms
2026
3
Above £5M revenue
Cardiff cohort
25
Incorporated since 2022
Cardiff cohort
Key facts
About 4% of the trading cohort reports turnover above £5M (3 of 73 firms) — the rest sits below that revenue band.
34% of the cohort was incorporated since 2022 (25 firms), so a sizeable share is in its first few filing cycles.
Human medicines activity can require an MHRA manufacturer’s licence or wholesale distribution licence, with good manufacturing practice and good distribution practice compliance.
Medicines require a marketing authorisation, and NHS access is subject to cost-effectiveness review by bodies such as NICE.
UK businesses performed £9.0 billion of pharmaceutical R&D in 2022, equivalent to 18% of all UK business R&D and 0.36% of UK GDP.
UK pharmaceutical exports were valued at £25.6 billion in 2023, ranking tenth among comparator countries.
The UK’s share of patients recruited to a subset of commercial clinical trials was 2.6% in 2022, ranking fourth among comparator countries.
Top Cardiff Pharmaceutical companies
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides aseptic pharmaceutical compounding services, preparing batch and bespoke sterile medicines for hospitals and healthcare providers across multiple therapy areas, including treatments for…
Targets healthcare organisations, hospital pharmacies and clinical teams needing batch or bespoke aseptic medicines across therapy areas for adult, paediatric and neonatal patient populations.
Financial Health
StableStable · Hiring · 3% CAGR over 4y
Location
NEURAXPHARM UK LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and markets pharmaceutical products for the treatment of central nervous system disorders. Portfolio includes medicines for conditions such as epilepsy, anxiety, migraine and chronic pain,…
Serves UK patients and members of the public affected by central nervous system disorders, alongside healthcare professionals such as doctors and pharmacists, carers and families.
Financial Health
StableStable · Hiring · 59% CAGR over 3y
Location
TREFOREST PHARMACY LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · -71% CAGR over 4y
Location
Kerwood Medical UK Limited
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable
Location
Seneca Group Holdings Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
CUPID PEPTIDE COMPANY LIMITED
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
GFC Diagnostics Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Gendra Pharma Ltd
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
YOZ HOLDINGS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak · 0% CAGR over 2y
Location
ARYAN PHARMA LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsManufactures and supplies pharmaceutical products including tablets, capsules, syrups, injections, ointments and herbal formulations. Produces oral and injectable medicines and distributes a…
Serves healthcare-sector customers, pharmaceutical buyers and patients/end users needing medicines across multiple dosage forms, including products suitable for all age groups; the site also refers…
Financial Health
StrongStrong · Hiring · 199% CAGR over 1y
Location
Cardiff Scintigraphics Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides pharmaceutical imaging services using gamma scintigraphy to track drug and medical device deposition in the body. Supports clinical studies and product development for inhaled, oral and…
Serves pharmaceutical developers, formulation teams, medical device developers and clinicians involved in inhaled, oral, nasal and targeted drug delivery, including sponsors of clinical studies…
Financial Health
WeakWeak · -2% CAGR over 5y
Location
Develops and commercialises pharmaceutical treatments for respiratory diseases. Conducts research and clinical development of inhaled therapeutics, including ensifentrine, targeting conditions such…
Serves respiratory patients, clinicians and healthcare organisations focused on chronic lung diseases such as COPD, non-CF bronchiectasis, cystic fibrosis and asthma.
Location
Argonaute RNA Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops RNA interference therapeutics using modified small interfering RNA (siRNA) to temporarily silence target genes. Researches bispecific and dual siRNA platforms and builds a pipeline of drug…
Targets strategic pharmaceutical partners and innovation-focused investors seeking RNA interference assets, particularly siRNA therapeutics for cardiometabolic and acute clinical indications, via…
Financial Health
StrongStrong · Hiring · 3% CAGR over 5y
Location
Solarius UK & Overseas Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -16% CAGR over 4y
Location
IMP Pharmaceutical Services Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides Qualified Person (QP) services including QP audits and release for clinical trial medicines, supports UK and EU importation of investigational medicinal products, and operates GMP…
Serves pharmaceutical and biotech companies, CROs and clinical trial sponsors managing investigational medicinal products for UK and EU clinical trials, including regulatory, CMC and supply-chain…
Financial Health
StrongStrong · Growing, Hiring · 12% CAGR over 4y
Location
MEDUCAN LIMITED
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StrongStrong · -86% CAGR over 2y
Location
SOFTGEL SOLUTIONS LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · Hiring · 32% CAGR over 4y
Location
G & C PHARMA LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures generic sterile injectable pharmaceuticals, including oncology and ophthalmic products. Provides contract development and manufacturing (CDMO) services, API production,…
Serves pharmaceutical companies and healthcare product marketers seeking B2B supply and CDMO partners across India, the US, Europe, Canada, Australia and other global markets.
Financial Health
HealthyHealthy · Growing, Hiring · 5% CAGR over 3y
Location
Provides contract research services for pharmaceutical and biotechnology companies, including clinical trial management across Phase I–III, early‑stage drug development consultancy, central…
Serves global pharmaceutical and biotechnology sponsors running early to late phase clinical studies, particularly in rare diseases, oncology, CNS, respiratory, and addiction research.
Location
IO Biotech Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops immune‑modulatory therapeutic cancer vaccines designed to stimulate T‑cell responses against IDO1‑ and PD‑L1‑expressing cells. Conducts research and clinical development of off‑the‑shelf…
Targets people with cancer, particularly melanoma and other tumor types, alongside oncology clinicians, clinical trial participants, and investors in cancer therapeutics.
Financial Health
HealthyHealthy · Hiring · 12% CAGR over 2y
Location
Unlock all 73 leads
Showing 20 of 73 — +53 more with verified decision-maker contacts, live data, and CRM sync.
How Cardiff Pharmaceutical companies work and how to sell to them
What they do
Cardiff pharmaceutical firms usually earn revenue from licensed supply, import, assembly, wholesaling, clinical-trial supply support and related quality services. Commercial models tend to mix product margin with per-batch charges, storage and handling fees, release documentation, validation work and recurring service retainers. Pricing is shaped by medicine category, batch volume, temperature-control needs, expiry risk, audit burden and the customer’s evidence requirements. These are not usually seat-based software businesses; the product is a regulated physical supply chain, often wrapped in documentation, responsible-person oversight, batch traceability and service-level commitments.
Who they sell to
Most sell into healthcare, pharmacy, wholesale, clinical research and regulated supplier channels rather than broad consumer markets. Typical buyers include hospital pharmacy teams, procurement managers, heads of quality, operations directors, clinical supply managers and finance leads where working-capital exposure matters. New customer onboarding can be slow because buyers need licence checks, quality questionnaires, supplier audits, insurance evidence and distribution records before placing repeat work. Contracting often runs through direct sales, negotiated supply agreements, framework call-offs or RFP processes, with spot orders used where the product is available and compliance risk is familiar.
What they buy
Most pharmaceutical firms in Cardiff tend to spend on systems and services that support controlled operations: quality-management software, document control, batch traceability, inventory management, temperature monitoring, pharmacovigilance workflow, finance systems, CRM, cyber security and secure cloud hosting. They also buy specialist accounting, regulatory consultancy, legal advice, insurance, recruitment, calibration, validation, clean-room or storage support, and outsourced logistics. Smaller firms may prefer tools that reduce audit preparation and manual record-keeping without forcing a full operational rebuild, while firms with repeat supply contracts usually care more about integration with stock, ordering and quality-release processes.
Why and how to sell to them
Pharmaceutical buyers tend to evaluate new suppliers when compliance workload rises, an MHRA inspection is due, a new licence is being prepared, a responsible-person or quality leader joins, or a new customer contract exposes gaps in traceability, stock control or documentation. Other triggers include import changes, cold-chain expansion, higher order volumes, credit pressure from inventory, and inspection findings that require corrective action. Outbound works best when it speaks to audit readiness, fewer manual hand-offs, evidence retention, batch-level visibility and lower operational risk, rather than generic productivity claims.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Cardiff
Related directories
Frequently asked questions
How many pharmaceutical companies are there in Cardiff?
What counts as a pharmaceutical company in this list?
Which are the largest pharmaceutical companies in Cardiff?
What do pharmaceutical companies in Cardiff actually do?
How does Cardiff pharmaceutical compare internationally?
How is this list built and how fresh is the data?
How big are the typical pharmaceutical companies in Cardiff?
Are these mostly new or established pharmaceutical companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 73 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.